Condition
Myeloproliferative Neoplasms (MPN)
Total Trials
5
Recruiting
1
Active
1
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (2)
P 1 (1)
P 3 (1)
Trial Status
Not Yet Recruiting2
Completed2
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07384039Not ApplicableNot Yet RecruitingPrimary
Exercise Training in Patients With Myeloproliferative Neoplasms
NCT07108023Not Yet Recruiting
Hematological Disorders in EHPVO Patients
NCT06740916Phase 3RecruitingPrimary
Long-term Efficacy of Once Daily Versus Twice Daily Aspirin in High-risk MPN Patients with Aspirin Resistance
NCT01816256Not ApplicableCompletedPrimary
Screening for Asymptomatic Portal Vein Thrombosis and Portal Hypertension in Patients With Philadelphia Negative Myeloproliferative Neoplasms
NCT01393509Phase 1Completed
The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies
Showing all 5 trials